RNS Number : 8957V
Genedrive PLC
09 March 2026

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN OR INTO ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION.

FURTHER, THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER FOR SALE OR SUBSCRIPTION OF ANY SECURITIES IN THE COMPANY OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON SUBSCRIBE FOR OR OTHERWISE ACQUIRE SHARES IN GENEDRIVE PLC IN ANY JURISDICTION.

genedrive plc
("genedrive" or the "Company")

Result of General Meeting

Manchester, UK - 9 March 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces that at the General Meeting, held today, all resolutions proposed were duly passed.

For information, details of the proxy voting are shown below:

Resolution	Votes For	Votes For (as % of votes cast)	Votes Against	Votes Against (as % of votes cast)	Vote Withheld
1	409,879,828	99.5%	2,261,522	0.5%	783,880
2	408,283,217	99.1%	3,855,873	0.9%	786,140
3	408,952,137	99.2%	3,222,381	0.8%	750,712
4	408,278,217	99.1%	3,896,701	0.9%	750,312

It is expected that Admission of the Conditional Subscription Shares, the Additional Subscription Shares, the Placing Shares, the Open Offer Shares and the Loan Conversion Shares will become effective at 8.00 a.m. on 10 March 2026. Following Admission, the Company will have 1,605,568,256 Ordinary Shares of £0.00015 in issue each with equal voting rights. No shares are held in treasury.

The full text of each of the resolutions is set out in the notice of General Meeting, copies of which are available on the Company's website (www.genedrive.com).

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the applicable announcement of the Fundraising made by the Company on 13 February 2026.

Enquiries:

Navigate to our Interactive Investor hub here: https://investors.genedrive.com/link/PZ3d7y

genedrive plc +44 (0) 161 989 0245
Dr Gino Miele (CEO) https://investors.genedrive.com/s/e0025c
Russ Shaw (CFO)

Peel Hunt LLP - Nominated Adviser and Broker +44 (0) 20 7148 8900
James Steel (Investment Banking)
Sohail Akbar / Nicholas Wilks (ECM)

Walbrook PR - Financial PR & IR Adviser +44 (0) 20 7933 8780
Anna Dunphy or genedrive@walbrookpr.com

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com)

genedrive plc is a pharmacogenetic testing company developing and commercialising a low cost, rapid, versatile and simple to use point of need pharmacogenetic platform for the diagnosis of genetic variants. This helps clinicians to quickly access key genetic information that will aid them make the right choices over the right medicine or dosage to use for an effective treatment, particularly important in time-critical emergency care healthcare paradigms. Based in the UK, the Company is at the forefront of Point of Care pharmacogenetic testing in emergency healthcare. Pharmacogenetics informs on how your individual genetics impact a medicines ability to work for you. Therefore, by using pharmacogenetics, medicine choices can be personalised, made safer and more effective. The Company has launched its two flagship products, the Genedrive® MT-RNR1 ID Kit and the Genedrive® CYP2C19 ID Kit, both developed and validated in collaboration with NHS partners and deployed on its point of care thermocycler platform. Both tests are single-use disposable cartridges which are ambient temperature stable, circumventing the requirement for cold chain logistics. The Directors believe the Genedrive® MT-RNR1 ID Kit is a worlds-first and allows clinicians to make a decision on antibiotic use in neonatal intensive care units within 26 minutes, ensuring vital care is delivered, avoiding adverse effects potentially otherwise encountered and with no negative impact on the patient care pathway. Its CYP2C19 ID Kit which has no comparably positioned competitor currently allows clinicians to make a decision on the use of Clopidogrel in stroke patients in 70 minutes, ensuring that patients who are unlikely to benefit from or suffer adverse effects from Clopidogrel receive an alternative antiplatelet therapeutic in a timely manner, ultimately improving outcomes. Both tests have undergone review by the National Institute for Health and Care Clinical Excellence ("NICE") and have been recommended for use in the UK NHS. The Company has a clear commercial strategy focused on accelerating growth through maximising in-market sales, geographic and portfolio expansion and strategic M&A, and operates out of its facilities in Manchester.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMUPUQPWUPQGGB